28 million euros to save human lives
MULHOUSE, France– CellProthera, a biotech company which offers the most advanced cell therapy for regeneration of the damaged heart muscle after myocardial infarction, announces it has raised €8,300,000 from private investors in 2016. These funds, supplements the20 million€ raised during the previous rounds, and will enable CellProthera to pursue its scientific development, complete its Phase I/IIb clinical trial in Europe and prepare its Phase III in Europe and North America.
Carried out in three phases, 100% of the capital increase comes from family offices, some of them with a history of supporting CellProthera in previous rounds.
New stakeholders, specializing in innovation and ground-breaking technology, particularly in the medical sector, have expressed real enthusiasm for CellProthera, its progress and potential .
The funds raised will be used for three main programs:
- Completion of the current phase I/IIb clinical trials. The company is also preparing the phase III trial, which involves setting up new cell therapy centers in Europe, the United States and Canada.
- Development of an industrial automate. This device is at the core of the treatment offered by CellProthera; from a simple blood test, it generates, on an industrial scale and by cellular multiplication, a graft of CD34 + stem cells “ProtheraCytes®” which is re-injected into the patient.
- CellProthera aims also to establish a foothold in Asia and will start a clinical trial in Singapore in 2017.
“With this new round, our investors have demonstrated their dedication and commitment to our project. The one million patients waiting for a therapy in Europe, the United States and Japan alone are grateful to them.”
Chairman & CSO
Chairman of the Supervisory Board
|Matthieu de KALBERMATTEN
Additional information and visuals are available on request from the press department
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.